Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7470-7477

  Jensen, Lars H ^a   Thougaard, Annemette V ^a   Grauslund, Morten ^a   Søkilde, Birgitte ^b   Carstensen, Elisabeth V ^b   Dvinge, Henrik K ^b   Scudiero, Dominic A ^d   Jensen, Peter B ^c   Shoemaker, Robert H ^e   Sehested, Maxwell ^a  

^a Rigshospitalet   (Denmark)

^b BioAlliance Pharma   (France)

^c FINSEN LABORATORY   (Denmark)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 CHLOROPURINE; 2 THIOPURINE; 2,6 DIMERCAPTOPURINE; 6 METHYLTHIOGUANINE; 6 O BENZYLGUANINE; 6 O CYCLOHEXYLMETHYLGUANINE; 6 O METHYLGUANINE; 9 BENZYLGUANINE; ACICLOVIR; ADENOSINE TRIPHOSPHATASE; CIRCULAR DNA; DITHIOTHREITOL; ETOPOSIDE; GUANINE DERIVATIVE; GYRASE INHIBITOR; MERCAPTOPURINE; NSC 35866; PURINE DERIVATIVE; RAZOXANE; TIOGUANINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG ACTIVITY; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CARCINOMA, SMALL CELL; CATALYSIS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HISTONES; HUMANS; LUNG NEOPLASMS; NOCODAZOLE; PHOSPHORYLATION; PURINES; THIOGUANINE;

EID: 23844497327     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0707     Document Type: Article

References (53)

1. Roca J, Wang JC. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 1994;77:609-16.
2. Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavable complexes. Curr Top Med Chem 2003;3:321-38.
3. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3: 430-40.
4. Akimitsu N, Kamura K, Tone S, et al. Induction of apoptosis by depletion of DNA topoisomerase IIα in mammalian cells. Biochem Biophys Res Commun 2003; 307:301-7.
5. Yang X, Li W, Prescott ED, Burden SJ, Wang JC. DNA topoisomerase IIβ and neural development. Science 2000;287:131-4.
6. 2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 2003;5:295-300.
7. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77.
8. Jensen PB, Sehested M. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 1997;54:755-9.
9. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998;1400: 155-71.
10. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003;99:167-81.
11. Hasinoff BB, Yalowich JC, Ling Y, Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 1996;7:558-67.
12. Ishida R, Iwai M, Hara A, Andoh T. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule. Anticancer Res 1996;16:2735-40.
13. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJ. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1- yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993;46:389-93.
14. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 1996;51:879-86.
15. Holm B, Jensen PB, Sehested M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 1996;38:203-9.
16. Holm B, Sehested M, Jensen PB. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 1998;4: 1367-73.
17. Jensen PB, Sorensen BS, Demant EJ, et al. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 1990;50:3311-6.
18. Holm B, Jensen PB, Sehested M, Hansen HH. In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin. Cancer Chemother Pharmacol 1994;34:503-8.
19. Sorensen M, Sehested M, Jensen PB. pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine. Biochem Pharmacol 1997;54:373-80.
20. Jensen PB, Sorensen BS, Sehested M, Grue P, Demant EJ, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 1994;54:2959-63.
21. Jensen LH, Renodon-Corniere A, Wessel I, et al. Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 2002;61:1235-43.
22. Wasserman RA, Austin CA, Fisher LM, Wang JC. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res 1993;53:3591-6.
23. Wessel I, Jensen LH, Jensen PB, et al. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the α isoform. Cancer Res 1999;59:3442-50.
24. Lindsley JE. Use of a real-time, coupled assay to measure the ATPase activity of DNA topoisomerase II. Methods Mol Biol 2001;95:57-64.
25. Jensen LH, Renodon-Corniere A, Nitiss KC, et al. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase IIα. Biochem Pharmacol 2003;66:623-31.
26. de Leij L, Postmus PE, Buys CH, et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 1985;45: 6024-33.
27. Cuttitta F, Rosen S, Gazdar AF, Minna JD. Monoclonal antibodies that demonstrate specificity for several types of human lung cancer. Proc Natl Acad Sci U S A 1981;78: 4591-5.
28. Louie KG, Behrens BC, Kinsella TJ, et al. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1985;45:2110-5.
29. Nadel EM, Greenberg J. Synergistic inhibitory action of a-methopterin and a diaminopyrimidine upon leukemia L1210 in mice. Cancer Res 1953;13:865-8.
30. Jensen PB, Sorensen BS, Sehested M, et al. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 1993;45:2025-35.
31. Kohn KW, Erickson LC, Ewig RA, Friedman CA. Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 1976;15:4629-37.
32. 49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 1998;58:1460-8.
33. Jensen LH, Dejligbjerg M, Hansen LT, Grauslund M, Jensen PB, Sehested M. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. BMC Pharmacol 2004;4:31.
34. 165Ser mutation in the Walker A ATP binding site of topoisomerase IIα. FEBS Lett 2002;520:161-6.
35. Hammonds TR, Maxwell A. The DNA dependence of the ATPase activity of human DNA topoisomerase IIα. J Biol Chem 1997;272:32696-703.
36. Harkins TT, Lindsley JE. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 1. A DNA-dependent burst in ATP hydrolysis. Biochemistry 1998;37:7292-8.
37. Kleymann G. Novel agents and strategies to treat herpes simplex virus infections. Expert Opin Investig Drugs 2003;12:165-83.
38. Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004; 10:RA247-54.
39. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997;3:837-47.
40. 6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J Med Chem 2004;47:3710-22.
41. Hasinoff BB, Wu X, Krokhin OV, et al. Biochemical and proteomics approaches to characterize topoisomerase II{α} cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase II{α}. Mol Pharmacol 2005;67:937-47.
42. Mojena M, Bosca L, Rider MH, Rousseau GG, Hue L. Inhibition of 6-phosphofructo-2-kinase activity by mercaptopurines. Biochem Pharmacol 1992;43:671-8.
43. Wang H, Mao Y, Zhou N, Hu T, Hsieh TS, Liu LF. ATP-bound topoisomerase ii as a target for antitumor drugs. J Biol Chem 2001;276:15990-5.
44. Morris SK, Baird CL, Lindsley JE. Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193. J Biol Chem 2000;275:2613-8.
45. Kaufmann SH, Svingen PA. Immunoblot analysis and band depletion assays. Methods Mol Biol 1999;94: 253-68.
46. Alexandrow MG, Hamlin JL. Chromatin decondensation in S-phase involves recruitment of Cdk2 by Cdc45 and histone H1 phosphorylation. J Cell Biol 2005;168: 875-86.
47. Contreras A, Hale TK, Stenoien DL, Rosen JM, Mancini MA, Herrera RE. The dynamic mobility of histone H1 is regulated by cyclin/CDK phosphorylation. Mol Cell Biol 2003;23:8626-36.
48. Renodon-Corniere A, Jensen LH, Nitiss JL, Jensen PB, Sehested M. Interaction of human DNA topoisomerase IIα with DNA: quantification by surface plasmon resonance. Biochemistry 2002;41:13395-402.
49. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 1994;91: 1781-5.
50. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003;100:10629-34.
51. Lindsley JE, Wang JC. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J Biol Chem 1993;268:8096-104.
52. Vaughn J, Huang S, Wessel I, et al. Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis. J Biol Chem 2005;280:11920-9.
53. Davies TG, Bentley J, Arris CE, et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 2002;9:745-9.